Navidea to present at BIO CEO conference

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Navidea Biopharmaceuticals, producers of the amyloid PET agent NAV4694, announced Feb. 2 that CEO Mark Pikett, PhD, would hold a presentation at the 16th annual BIO CEO and Investor Conference taking place at the Waldorf Astoria in New York City, Feb. 10-11.

During his talk, Pykett will be discussing how the company is performing and providing an agenda for research and development and up and coming programs for commercialization. In the past year, Navidea saw the FDA approval of technetium 99m tilmanocept (Lymphoseek) and continues to develop NAV4694; NAV5001, also indicated for neurodegenerative diseases including Parkinson's and dementia with Lewy bodies; and RIGScan, a novel radiolabeled monoclonal antibody for oncologic imaging. 

Pykett's speech is scheduled to take place Monday, Feb. 10, at 1:30 pm EST. The general public can listen in on the live webcast of his talk, which will be available for replay an hour after the live webcast for an estimated 30 days. Plug in to the webcast here.

The BIO CEO and Investor Conference is reputed to be the largest investment meeting focused exclusively on emerging and established biotech companies.

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.